Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Figure 1 Flowchart of the patient selection. CRC: Colorectal cancer; PD-1: Programmed death-1; MSI-H: Microsatellite instability-high; dMMR: Mismatch repair deficient; F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.

Figure 2 Kaplan-Meier analysis. A: Kaplan-Meier curves of progression-free survival in patients treated with Regorafenib (R), regorafenib plus programmed death-1 inhibitors (RP), fruquintinib (F), and fruquintinib plus programmed death-1 (FP); B: Kaplan-Meier curves of overall survival in patients treated with R, RP, F, and FP. ^aP < 0.05, and the difference is statistically significant. F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.

Figure 3 Subgroup analysis of progression-free survival and overall survival stratified by clinical factors. A: Less than 65 years old; B: Primary lesion of the right-sided colon; C: BRAF mutations; D: Less than three sites of metastatic disease; E: Without lung metastases; F: With liver metastases; G: The Eastern cooperative oncology group score of 0-1. ^aP<0.05, and the difference is statistically significant. F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.

Figure 4 Gene mutation profile of patients who achieved complete response or had progression-free survival greater than 6 months. F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.